The conversation discusses the effectiveness of Exosomes as a hair loss treatment. A user recalls a doctor on Youtube showcasing successful results from using Exosomes.
Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.
Keratin microspheres may offer additional mechanisms to combat hair loss compared to minoxidil. The process to create these microspheres is relatively simple and can be done at home with basic equipment.
Capilia Longa is considered as an alternative to Minoxidil for beard growth, with some users reporting positive results. However, concerns exist about its effectiveness and high cost, especially for scalp use.
A new stem cell therapy shows promise in treating hair loss, but skepticism remains about its availability. Users humorously discuss the effectiveness of treatments on mice compared to humans.
The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.
The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.
User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
Hair loss discussion with a focus on a single resilient hair, jokingly called "chad hair," that remains despite hairline receding. Some users suggest microneedling and hair follicle cloning as potential treatments.
Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.
The conversation is about someone seeking advice on choosing between stem cell therapy and PRP for treating hair loss, asking for personal results, side effects, overall satisfaction, and recommendations from others.
Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.
Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
Celery juice is discussed as a potential treatment for crown balding, with skepticism from users. The conversation highlights differences between alopecia areata and male pattern baldness.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.